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Abstract
Purpose Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby 
increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites 
produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the 
body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, 
and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between 
dietary-AGEs and breast cancer.
Methods We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative 
(ER−) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to 
reduce circulating AGE levels in ER+ breast cancer survivors.
Results An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of 
ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept 
study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast 
cancer survivors.
Conclusions There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the 
potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community 
health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treat-
ment outcomes.
Keywords Advanced glycation end product · Estrogen receptor · Breast cancer · Tamoxifen resistance · Lifestyle 
intervention
Introduction
Breast cancer is the 2nd leading cause of new cancer cases 
in the US, where more than 3 million breast cancer survi-
vors reside. Lifestyle behaviors such as an unhealthy diet 
and physical inactivity are modifiable prognostic factors that 
may have distinct molecular consequences on breast cancer 
outcomes. Despite a current consensus that exercise and a 
healthy diet may improve breast cancer prognosis, little is 
known about their positive effects on the biological path-
ways involved in breast tumor biology.
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Advanced glycation end products (AGEs) are reactive 
metabolites produced endogenously as a by-product of sugar 
metabolism as well as the oxidation of biological molecules 
[1–3]. AGEs irreversibly accumulate in our tissues causing 
pathogenic effects on organ homeostasis, genetic fidelity, 
protein function, and cell signaling cascades [1–3]. Signifi-
cantly, an unhealthy diet, high in sugar, fat, and highly pro-
cessed foods along with a sedentary lifestyle also contribute 
to the AGE accumulation pool to contribute to chronic dis-
ease development and complications [4–6]. Increases in the 
AGE accumulation pool lead to the perpetual activation of 
cancer-associated cell signaling cascades including MAPK 
(mitogen-activated protein kinase) and AKT (protein kinase 
B) leading to aberrant transcriptional activity, immune func-
tion, and oxidative stresses [7].
The pathogenic effects of AGEs are often mediated 
through activation of the cognate receptor for AGE (RAGE) 
[1–3, 6]. RAGE knockdown in ER+ MCF7 cells decreases 
17α-ethinyl-estradiol-dependent proliferation and sur-
vival through changes in AKT, CCND1 (cyclin D1), and 
BCL2 (B-cell lymphoma 2) [8]. AGE-RAGE signaling 
promotes the activation of redox-responsive transcription 
factors including NFkB (nuclear factor kappa-light-chain-
enhancer of activated B cells) and AP-1 (activator protein 1) 
to increase MAPK and ERK (extracellular signal-regulated 
kinase) signaling [9]. Crosstalk between ERα and NFkB 
can stimulate cell proliferation and survival and contribute 
to tamoxifen resistance [10]. Recent data also indicate that 
inhibition of ERα by endocrine therapies such as tamoxifen 
may release NFκB from ERα-driven inhibition, possibly 
resulting in tamoxifen resistance and NFκB-driven tumor 
progression [11]. Additionally, several outcome signatures 
derived from women treated with tamoxifen have implicated 
immune response as a common mechanism contributing to 
tamoxifen resistance [12–14].
Given the common signaling cascades involved in AGE 
pathogenesis and ERα regulation, we examined the ability 
of AGEs to augment ERα phosphorylation and tamoxifen 
resistance, and tested the ability of a defined lifestyle inter-
vention program to lower AGE levels in overweight/obese 




For AGE analysis, serum samples were obtained from the 
Hollings Cancer Center Tissue Biorepository at the Medical 
University of South Carolina (MUSC). In total, 20 well and 
20 poorly differentiated serum samples (1 ml of each) were 
selected from female breast cancer patients which had been 
stored between 1 and 5 years since diagnosis.
Tissue microarray’s were obtained from US BioMax 
(Rockville, MD) and contained 96 samples of non-cancer, 
hyperplastic, and cancerous tissue from 48 patients. Patho-
logical data available from each patient included tumor 
grade and receptor status. Tissue for mass spectrometry 
analysis was obtained from breast cancer patients recruited 
in Baltimore hospitals between 1993 and 2003, as previously 
described [15, 16].
Immunohistochemical (IHC) staining
IHC staining was performed to examine AGE levels in 
tissue as previously published [4]. IHC scores were cal-
culated using the formula: intensity X % positive tumor 
cells. Intensity staining was scored as follows: 1—weak, 
2—intermediate, 3—strong, and 4—very strong. Percent 
positive tumor cells were scored as follows: 1—less than 
10%, 2—10–30%, 3—30–60%, and 4—60–100% positive 
cells by a pathologist.
AGE ELISA
To examine the levels of AGEs in serum, 96-well format 
Oxi-select ELISA’s (Cell Biolabs, San Diego, CA) were 
used as directed by the manufacturer. All samples were nor-
malized to total protein concentration [4].
Mass spectrometry analysis
Carboxymethyllysine (CML) and carboxyethyllysine (CEL) 
and the internal standards (IS) CML-13C4/CEL-13C4 were 
obtained from Sigma-Aldrich/Santa Cruz. The CML/CEL 
stock solutions were prepared in water as 1 mg/mL solu-
tions. The CML/CEL calibration standards, 0.8–100 ng/mL, 
were prepared by serial dilution of the stocks with PBS. 
The working IS solution (10 ng/mL each of the 13C4) was 
prepared by diluting the IS stocks with 0.24N trichloroacetic 
acid (TCA) solution. The tissue samples were wet weighted 
and homogenized in PBS using the Bead Ruptor (Omni), 
followed by centrifugation (10 min/16 kg). 15 µL of the tis-
sue supernatant or calibration standards were vortex mixed 
with 75 µL IS solution. After centrifugation (10 min/16 kg), 
the solutions were transferred to injection vials for LC/MS/
MS. LC was performed with a Shimadzu 20AC-XR system. 
The injection volume was 40 µL. Separation was achieved 
with a 2 × 150 mm, 3 µm SS-C18 column (Imtakt). Mobile 
phase A was 0.1% formic acid in water and mobile phase 
B was 50 mM ammonium acetate/80% methanol. The flow 
rate was 300 µL/min and peaks were eluted with a 8-min 
gradient. MS/MS was performed with a TSQ Vantage triple 
quadrupole mass spectrometer (Thermo Fisher Scientific) 
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operating in selected reaction monitoring (SRM) mode 
with positive electrospray ionization. The target peaks were 
detected using the following m/z precursor > product ions: 
CML (205 > 84); CML-13C4 (209 > 88); CEL (219 > 84); 
CEL-13C4 (223 > 88). CML and CEL in the supernatant (Y 
ng/mL) were determined using the Thermo Xcalibur soft-
ware. Calibration curves, constructed by plotting the peak 
area ratios vs. standards, were fitted by linear regressions 
(R2 = 0.99). The peak area ratios were calculated by dividing 
the peak areas of CML or CEL by the peak area of CML-
13C4 or CEL-13C4, respectively.
Cell culture
MCF7 and T47D cell lines were purchased from ATCC 
(Manassas, VA). Cells were incubated at 37 °C, 5%  CO2 
in their respective media. Cells were cultured up to 30 pas-
sages before being replaced from low passage stocks. Myco-
plasma-negative cultures were ensured by PCR testing. Cells 
were monitored throughout with consistent morphology and 
doubling-time. T47D cells were incubated in RPMI (Fisher 
Scientific, Fair Lawn, NJ) with 10% fetal bovine serum 
(Fisher Scientific) and 1% Penicillin/Streptomycin (Fisher 
Scientific). MCF7 cells were incubated in DMEM/High 
Glucose media (Fisher Scientific) containing 10% FBS and 
1% Penicillin/Streptomycin with the following additives: 1% 
MEM Non-essential Amino Acids, 1% Sodium Pyruvate, 1% 
Sodium Bicarbonate, and 1% insulin (all obtained from Life 
Technologies, Grand Island, NY).
Exogenous AGE treatment
Exogenous BSA-AGE and control BSA were produced as 
previously published [17]. For examination of AGE treat-
ment, cells (400,000) were seeded into each well of a 6-well 
plate in serum-free media overnight before treatment with 
AGE metabolite (50ug/ml). Effects of AGE treatment on the 
phosphorylation of ERα, AKT, and ERK was assessed by 
Western blot as indicated below. Pharmacological targeting 
of the MAPK/ERK and PI3K/AKT pathways in the pres-
ence of AGE was achieved in serum-free media using the 
molecular inhibitors U0126 (ERK) and LY294002 (AKT) 
(Cell signaling Technology, Danvers, MA) at a concentration 
of 10uM for 12 h before exposure to AGE metabolites. To 
examine the effects of AGE metabolite on tamoxifen resist-
ance, cells (3,000) were seeded into each well of a 96-well 
plate and were treated with the active metabolite of tamox-
ifen, 4-hydroxytamoxifen (0, 10 µM) (Sigma-Aldrich, St. 
Louis, MO) in combination with varying doses of AGEs 
(0, 5 µg/mL, 10 µg/mL, 50 µg/mL). After 24, 48, and 72 h, 
SRB staining was used to quantify cell growth as described 
previously [18].
Western Blot analysis
For isolation of total protein, cells at 70–80% confluence 
were washed twice with ice cold 1xPBS, and were lysed in 
radio-immunoprecipitation assay (RIPA) buffer containing 
protease and phosphatase inhibitors (Sigma). Equal amounts 
of total protein (50 µg) were resolved by 10% SDS-PAGE 
and subjected to Western blot analyses using ECL sys-
tem (Pierce-Fisher Scientific, Rockford, IL). Total protein 
lysates were examined using primary antibodies against 
total ERα, phosphorylated ERα-ser118 (p-ERα (ser118)), 
phosphorylated ERα-ser167 (p-ERα (ser167)), total ERK, 
phosphorylated-ERK (pERK), total AKT, phosphorylated-
AKT (pAKT), and GAPDH (all obtained from Cell Signal-
ing Technology).





AGE levels are elevated in ER+ breast cancer 
patients
Breast tumor microarrays were stained using antibodies 
specific for AGE. Staining intensity in tumor tissue varied 
by stage and differentiation (Fig. 1). Highest staining for 
epithelial AGE was observed in carcinoma and then hyper-
plasia tissue when compared to non-cancer tissue speci-
mens (Fig. 1a). In contrast, stromal AGE in the same tissue 
samples was highest in non-cancer and hyperplasia tissue 
(Fig. 1b). In a separate set of serum samples obtained from 
the MUSC biorepository, analysis by ELISA shows that cir-
culating AGE levels are higher in serum from patients with 
well-differentiated tumors compared to poorly differentiated 
(Fig. 1c). When stratified by ER status, ER+ patients had 
significantly higher circulating AGE levels than ER- patients 
(Fig. 1d).
Nε‑carboxymethyllysine and  Nε‑carboxyethyllysine 
are elevated in breast tumors
Levels of CML and CEL were assessed in a separate set of 
19 non-cancerous and 18 cancerous breast tissue samples 
using liquid chromatography–tandem mass spectrometry 
(LC/MS/MS). Compared to non-cancerous tissue, both 
CML (Fig. 1e) and CEL (Fig. 1f) levels were elevated in the 
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tumor tissues. Average levels of CML and CEL in the tumor 
samples were 42.44 ng/µg and 18.55 ng/µg, respectively, 
compared to 21.29 ng/µg and 9.468 ng/µg in non-cancerous 
tissue. When stratified by ER status both CML and CEL lev-
els were higher in ER+ and ER− tumor tissue compared to 
non-cancerous but this only reached statistical significance 
Fig. 1  AGE levels are elevated 
in ER+ breast cancer patients. 
a Quantification of epithelial 
AGE levels in breast normal 
and tumor tissue using IHC 
staining. b Quantification of 
stromal AGE levels in breast 
tumor tissue using IHC staining. 
c Quantification of circulat-
ing AGE levels, analyzed by 
ELISA, in serum from breast 
cancer patients stratified by 
well and poorly differentiated 
tumors. d Quantification of cir-
culating AGE levels, analyzed 
by ELISA in serum from breast 
cancer patients stratified by ER 
status. e Quantification of CML 
levels in non-cancer and breast 
tumor tissue using LC/MS/
MS. f Quantification of CEL 
levels in non-cancer and breast 
tumor tissue using LC/MS/
MS. g Quantification of CML 
levels, analyzed by LC/MS/MS 
in non-cancer and breast tumor 
tissue stratified by ER status. h 
Quantification of CEL levels, 
analyzed by LC/MS/MS in non-
cancer and breast tumor tissue 
stratified by ER status
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for the ER+ comparison (Fig. 1g, h). Collectively these data 
show that both CML and CEL are elevated in the tumor of 
breast cancer patients and may trend towards higher levels 
in ER+ patients.
AGE treatment activates pathways associated 
with ER regulation and tamoxifen resistance
We first examined whether AGE stimulates AKT and ERK 
activity in ER+ breast cancer cells. Cells were treated with 
BSA-AGE (50 μg/mL), and the effects on AKT (ser473) 
and ERK phosphorylation (ser202/tyr204) assessed. Control 
cells were treated with BSA [17]. We observed a significant 
increase in both AKT and ERK phosphorylation in both 
MCF7 (Fig. 2a) and T47D (Supplementary Fig. 1a) cell lines 
in response to AGE treatment in a time-dependent manner.
Phosphorylations of ser118 and ser167 within the ligand-
independent activation domain of ERα are two residues 
emerging as potential predictive markers for patient response 
to tamoxifen [19, 20]. MCF7 and T47D cells were treated 
with 50ug/mL of AGEs for 30 min and were then examined 
for phosphorylation of ERα at residues ser118 and ser167. 
100 nM estradiol, one of the key estrogenic ligands for the 
receptor, was used as a positive control to ensure optimiza-
tion of phospho-specific antibodies. In both cell lines and at 
both residues, we found a significant increase in phospho-
rylation of ERα following AGE treatment when compared to 
untreated control with no overall change in total ERα levels 
(Fig. 1b and Supplementary Fig. 1b). We also examined the 
influence of AGE treatment on the phosphorylation of ERα 
at ser167 over a time course of 1 h in MCF7 and T47D 
cells and observed that the AGE-mediated phosphorylation 
Fig. 2  AGE treatment activates 
pathways associated with ER 
regulation and tamoxifen treat-
ment. a Western blot analysis 
of time-dependent AKT and 
ERK phosphorylation after 
treatment with AGE (50ug/
mL) in MCF7 breast cancer 
cells. b Western blot analysis 
of ERα phosphorylation after 
treatment with AGE (50ug/mL) 
in MCF7 breast cancer cells. c 
Western blot analysis of AKT 
and ERK phosphorylation after 
treatment with AGE (50ug/mL) 
in MCF7 cells in the presence 
of AKT inhibitor. d Western 
blot analysis of AKT and ERK 
phosphorylation after treat-
ment with AGE (50ug/mL) in 
MCF7 cells in the presence of 
ERK inhibitor. e Cytotoxicity 
assay of MCF7 cell proliferation 
after treatment with tamoxifen 
(10uM) in the presence of 
increasing AGE concentration. 
f Cytotoxicity assay of MCF7 
cell proliferation after treatment 
with tamoxifen (20 μM) in the 
presence of increasing AGE 
concentration
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of ERα is transient in nature with a peak around 15–30 min 
following initial treatment (Supplementary Fig. 1c, d).
To determine if ERK and AKT signaling are required for 
AGE-mediated ERα phosphorylation, both ERK and AKT 
pathways were pharmacologically inhibited in the presence 
of AGE. In MCF7 cells, inhibition of AKT with Ly294002 
and inhibition of ERK with the MEK inhibitor U0126 sig-
nificantly reduced phosphorylation of ERα ser167 (Fig. 2c) 
and ser118 (Fig. 2d), respectively, in the presence (50ug/mL) 
of AGE metabolite. Similar results were observed in T47D 
cells treated in the same manner (Supplementary Fig. 1e, f).
To explore a potential role for AGE metabolites in tamox-
ifen resistance, we treated MCF7 and T47D cells with vary-
ing levels of AGEs in the presence of tamoxifen (10 μM). 
Cells were cultured for 24, 48, and 72 h and cell proliferation 
was assessed using a sulforhodamine B (SRB) colorimetric 
assay [18]. The proliferation of cells in the absence of AGE 
was inhibited by treatment with tamoxifen in both cell lines 
as expected (Fig. 2e, f). When tamoxifen was added to the 
cells in the presence of increasing concentration of AGE 
(from 5 to 50 μg/ml), a dose-dependent restoration of prolif-
eration was observed in both MCF7 and T47D cells (Fig. 2e, 
f). The data outlined in Fig. 2 identify a mechanistic link 
between sugar-derived metabolites, AGEs, and ERα regula-
tion which may provide a direct biological consequence of 
poor lifestyle that may directly impact tamoxifen efficacy.
Lifestyle intervention reduces the levels of AGE 
in the circulation of ER+ breast cancer survivors
In a proof of concept pilot study, we tested the ability of 
a defined lifestyle intervention to lower AGE levels in ten 
overweight/obese post-menopausal women with non-meta-
static stage I–III ER+ breast cancer. Characteristics for the 
ten participants are summarized in Table 1. The interven-
tion consisted of a focused 11-week physical activity (PA) 
and dietary counseling intervention that took place within 
the established clinical setting of the Medical University 
of South Carolina (MUSC) cardiopulmonary rehabilitation 
center (Cardiac-Rehab) (Fig. 3a) (Supplementary Methods).
The pilot study showed a favorable 67% consent rate. Of 
the 15 enrolled patients, 12 completed the 11-week program; 
2 participants were later found to be ineligible because of 
past weight loss surgery that was not reported at enrollment 
(and were not included in this analysis). A further 3 dropped 
out due to competing medical conditions and unwilling-
ness to continue resulting in a 73% adherence rate. Overall 
adherence to the weekly exercise sessions at cardiac rehab 
was 82.3% with 50% of participants showing 100% adher-
ence to the twice weekly visits. A modest but general trend 
of improvement was observed in clinical and laboratory 
measures as a result of the 11-week intervention (Table 2 
and Supplementary Table 1). Statistical significance was 
observed for diastolic blood pressure (p = 0.01) and lipid 
levels (p = 0.05). An analysis of the Fitbit data showed a 
significant increase in overall very active minutes (Fig. 3b) 
which coincided with a concurrent increase in average cal-
ories burned (Fig. 3c) when compared to baseline assess-
ments, demonstrating the potential health benefits of the 
study intervention for cancer survivors. Seven (70%) par-
ticipants showed reduced calorie intake as a result of the 
dietary intervention while three (30%) increased their calorie 
intake (Fig. 3d). While some participants showed individual 
reductions (Supplementary Fig. 2a–c), an analysis of aggre-
gate diet composition showed no significant difference in 
fat, carbohydrate, and protein composition (Supplementary 
Fig. 2d). Maximal oxygen consumption (VO2 max) was 
significantly increased at the end of the intervention when 
compared to baseline levels (Fig. 3e). An assessment of daily 
dietary-AGE content was carried out on the basis of 7-day 
food records; the assessment was estimated from a database 
of ~ 560 foods and was expressed as AGE Equivalents (Eq/
day) (1 AGE equivalent = 1000 kilounits) [21]. Dietary-AGE 
content was consistently reduced in the participants taking 
part in the intervention (Fig. 3f). Compared to baseline val-
ues, nine participants (90%) showed significant reductions 
in dietary-AGE intake at week 8, which maintained at week 
11 for eight participants (80%). In general, participants that 
showed significant reductions in dietary-AGE intake at 
week 8 and week 11 also showed significant reductions in 
circulating AGE levels when fasting serum samples were 
analyzed by ELISA (Fig. 4a). Only two patients had higher 
circulating AGE levels at week 11 than baseline. Median 
AGE levels at baseline were 53ug/ml compared to 23ug/ml 
at week 8 and 38 μg/ml at week 11 (Fig. 4b). These findings 
represent an about 30–60% reduction in the AGE levels. 
An examination of circulating AGE levels at 13 weeks post 
intervention (24 weeks) showed a return to pre-intervention 
levels in all participants (Fig. 4C). Interleukin 6 (IL6) and 
C-reactive protein (CRP) are often used to assess inflam-
matory changes induced by diet and exercise. An analysis 
of IL6 (Fig. 4d) and CRP (Fig. 4e) levels by ELISA in the 
same AGE-assessed samples revealed no significant differ-
ences at any time point.
Discussion
Given the increasing consumption of dietary-AGEs due 
to their inherent relationship with a Western lifestyle, it is 
important to elucidate their potential contribution to the car-
cinogenic process. Lifestyle and pharmacological interven-
tions that lower AGE levels may then be viable options to 
reduce breast cancer incidence and improve prognosis in 
those living with breast cancer. We have identified a mecha-
nistic link between AGEs and ERα regulation which may 
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provide a direct biological consequence of poor lifestyle that 
may directly impact tamoxifen efficacy.
About 70% of all invasive breast cancers express the 
estrogen receptor, making it of utmost importance to cre-
ate more effective treatments, reduce resistance to current 
treatments, and improve outcomes through lifestyle inter-
ventions for these patients. The data presented suggest that 
AGE levels may be highest in ER+ tumors when compared 
to ER− and that, at least in vitro, elevated AGE levels can 
inhibit the growth inhibitory effects of tamoxifen. Studies 
have shown an association between certain estrogen-
independent phosphorylation sites on ERα and tamoxifen 
resistance [19, 20]. Here, we have shown that two of these 
residues, ser118 and ser167, are activated in response to 
AGE exposure and that AGE treatment reduces cell sen-
sitivity to tamoxifen treatment. By identifying an AGE-
mediated effect on sensitivity to this drug, we can add to 
the existing knowledge base that is reinforcing the need for 
more personalized medicine in cancer, including imple-
mentation of specific lifestyle changes. By characterizing 
Table 1  Participant information 
for the lifestyle intervention
Table of patient characteristics
GED general education development, ER estrogen receptor, PR progesterone receptor, HER human EGF 
receptor
Characteristic n (%)
Age, mean (range) 56 (46–68) years
Age at diagnosis, mean (range) 57 (46–67) years
Race
 European American 6 (60)
 African American 4 (40)
Education level
 < 12 years 1 (10)
 High school graduate or GED 1 (10)
 Some college 5 (50)





Time since diagnosis (from date of study registration)
 1–6 months 4 (40)
 7–12 months 5 (50)
 13–18 months 0 (0)
 19–24 months 0 (0)










 ER/PR+ Her2− 10 (10)
Treatment type all participants had had surgery apart from 1
 Radiation therapy only 1 (10)
 Hormone therapy only 1 (10)
 Radiation therapy + chemotherapy 1 (10)
 Radiation therapy + hormone therapy 4 (40)
 Radiation therapy + chemotherapy + hormone therapy 3 (30)
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a functional role of AGEs in the development of tamox-
ifen resistance, we suggest that targeted therapies for this 
type of cancer can potentially become more effective 
through modification of diet, increased physical activity, 
and/or through pharmacological strategies to reduce AGE 
accumulation. While this in vitro work is an important 
foundation in investigating a role for AGEs in tamoxifen 
resistance, it fails to address the complexity of the tumor 
microenvironment and intracellular signaling. However, 
it is still an important first step and future studies will 
address the importance of AGE in mediating resistance to 
tamoxifen especially when those studies use in vivo mouse 
models to validate the AGE-mediated effects we observed 
in our cell line studies.
Many of the foods that we consume contribute to the 
AGE accumulation pool in the body [21–24]. The Western 
lifestyle consisting of foods high in sugar, protein, and fat 
and low in fruit, grains, and vegetables is particularly AGE 
laden and associated with an increased chronic disease risk 
[21–24]. AGE and AGE precursors are naturally present in 
uncooked meats; frying, grilling, or roasting leads to a sig-
nificant increase in AGE formation as we cook our foods 
[5, 6]. Similarly, food processing and manufacturing also 
accelerates AGE formation and food manufacturers regularly 
add AGEs directly during processing in order to improve 
food appearance and taste 21.
A major goal of the proof of concept lifestyle intervention 
was to assess the clinical infrastructure of cardiac rehab as 
a platform for breast cancer survivors. This clinical setting 
was chosen because the goal of cardiac rehab is to provide 
supervised exercise training to enable patients with cardio-
vascular disease to achieve their optimal physical function-
ing [25–27]. The study shows a favorable 67% consent rate 
and 73% adherence rate and resulted in an increased level 
of PA, promoted a healthier diet, and was shown to be a 
successful strategy for reducing circulating AGE levels in 
breast cancer patients. This study identifies AGEs as a ubiq-
uitous molecular indicator of lifestyle change. Both dietary 
and circulating AGE levels were consistently lowered by 
the cardiac rehab lifestyle intervention, while we observed 
no change in the more recognized bio-behavioral markers 
IL6 and CRP.
In summary, AGE metabolite levels may represent a sen-
sitive ubiquitous bio-behavioral marker for the molecular 
assessment of lifestyle change. Dietary-AGE restriction has 
been previously shown to reduce circulating AGE levels in 
patients with chronic kidney disease, metabolic syndrome, 
and diabetes [28]. As the intervention for this study was a 
proof of concept exercise, the results should be interpreted 
with caution due to a number of limitations including the 
small cohort of participants in the intervention which lim-
its the ability to make conclusions beyond the feasibility of 
the intervention. However, the present study may provide 
a defined framework for future studies seeking to improve 
cancer outcomes and quality of life among cancer survivors 
across wide racial/ethnic, geographic, and socioeconomic 
strata.
Fig. 3  Lifestyle intervention reduces dietary-AGE intake in 
ER+ breast cancer survivors. a Conceptual Framework for the PA 
and dietary intervention. b Average very active minutes achieved 
by participants during the 11-week lifestyle intervention as assessed 
from Fitbit data. c Average calories burned by participants dur-
ing the 11-week lifestyle intervention as assessed using 7-day food 
records. d Calorie intake for each participant as assessed using 7-day 
food records. e Average VO2 max at baseline and completion of the 
11-week lifestyle intervention. f Dietary-AGE intake per partici-
pant at baseline, week 8, and week 11 of the lifestyle intervention as 
assessed using 7-day food records
◂
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Table 2  Average pre- and post- intervention clinical and laboratory characteristics
The bold numbers are statisticaly significant
Table of clinical and laboratory measures taken during the intervention
a 24-h fasting blood draws
b Glucose: pre-intervention missing = 1 (n = 9)
c Insulin: pre-intervention missing = 3 (n = 7); post-intervention missing = 1 (n = 9)
d Lipid levels: post-intervention missing = 1 (n = 9)
e Hemoglobin A1C: post-intervention missing = 1 (n = 9)
f HOMA-insuling resistance: pre-intervention missing = 4 (n = 6); post-intervention missing = 1 (n = 9)
g HOMA-Insulin resistance formula: (insulin × glucose)∕405








 Height (cm) 164.3 (160.0–172.7) 164.3 (160.0–172.7) 0.0
 Weight (kg) 90.9 (75.3–110.3) 89.5 (71.5–109.5) − 1.4 0.34
 Pulse (bpm) 80 (67–95) 77 (62–88) − 2.9 0.31
 Respiratory rate (bpm) 17 (16–20) 18 (16–20) +0.9 0.17
 Waist circumference (cm) 107.0 (94.0–124.0) 105.6 (91.4–125.1) − 1.1 0.50
 Hip circumference (cm) 116.7 (106.7–125.0) 116.8 (108–141.0) 0.1 0.97
 Waist:hip ratio (cm) 0.90 (0.83–0.95) 0.90 (0.83–1.02) 0.0 0.55
 Body mass index (kg/m2) 33.8 (27.5–43.09) 33.2 (26.4–42.8) − 0.5 0.30
 Systolic blood pressure (mmHg) 137 (117–166) 129 (112–144) − 7.3 0.06
 Diastolic blood pressure (mmHg) 84 (74–100) 76 (62–94) − 8.2 0.01
Laboratory  characteristicsa
 Glucose (mg/dl)b 117 (92–139) 117 (102–141) + 1.1 0.65
 Insulin (mcILI/m1)c 24.4 (11.7–43.8) 17.1 (9.1–31.4) − 4.5 0.09
 Lipid Levels (mmol/L)d 200 (166–234) 186 (146–236) − 10.6 0.049
 Hemoglobin A1C (mmolimo1)e 6.1 (5.1–7.6) 6.0 (5.3–7.2) − 0.1 0.65
 HOMA-insulin  resistancef,g 7.2 (3.5–15.0) 5.1 (2.8–10.2) − 1.6 0.11
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Fig. 4  Lifestyle intervention 
reduces the levels of AGE in 
the circulation of ER+ breast 
cancer survivors. a Circulatory 
AGE levels per participant at 
baseline, week 8 and week 11 
of the lifestyle intervention as 
assessed by ELISA. b Average 
AGE levels at baseline, weeks 8 
and 11 for all participants of the 
lifestyle intervention as assessed 
by ELISA. c Percent change 
in circulating AGE levels at 
baseline, weeks 8 and 11 for all 
participants at of the lifestyle 
intervention and 13 weeks after 
the intervention had ended as 
assessed by ELISA. d Aver-
age IL6 levels at baseline and 
at completion for all partici-
pants of the 11-week lifestyle 
intervention as assessed by 
ELISA. e Average CRP levels at 
baseline and at completion for 
all participants of the 11-week 
lifestyle intervention as assessed 
by ELISA
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